Ultragenyx Pharmaceutical Revenue and Competitors

Novato, CA USA

Location

$185M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Ultragenyx Pharmaceutical's estimated annual revenue is currently $359.6M per year.(i)
  • Ultragenyx Pharmaceutical received $350.0M in venture funding in February 2019.
  • Ultragenyx Pharmaceutical's estimated revenue per employee is $243,275
  • Ultragenyx Pharmaceutical's total funding is $185M.
  • Ultragenyx Pharmaceutical's current valuation is $4.9B. (January 2022)

Employee Data

  • Ultragenyx Pharmaceutical has 1478 Employees.(i)
  • Ultragenyx Pharmaceutical grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

Ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. Our company is led by an experienced management team in rare disease therapeutics. Recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. We are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. We are creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. We believe that we can deliver significant value to our patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. We are looking for highly motivated individuals to join our team in an exciting biotechnology environment. If you are looking for a meaningful position that has the ability to transform the lives of patients and be part of a high performance team focused on the same goal, this is the opportunity you have been waiting for.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$185M

Total Funding

1478

Number of Employees

$359.6M

Revenue (est)

9%

Employee Growth %

$4.9B

Valuation

N/A

Accelerator

Ultragenyx Pharmaceutical News

2022-04-19 - Ultragenyx to Host Conference Call for First Quarter 2022 ...

Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare...

2022-04-17 - Ultragenyx Pharmaceutical (NASDAQ:RARE) Downgraded to ...

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of...

2022-04-17 - Ultragenyx Issues Inaugural Environmental, Social and ...

Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare...

2021-09-09 - MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

NOVATO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Mepsevii® (vestronidase alfa) has been approve ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$725M2354-20%N/A

Ultragenyx Pharmaceutical Funding

DateAmountRoundLead InvestorsReference
2011-06-21$45.0MATPG Biotech , Fidelity BiosciencesArticle
2014-07-15$60.2MUndisclosedJ.P. Morgan Securities LLCArticle
2015-02-06$186.3MUndisclosedMorgan StanleyArticle
2015-07-16$UndisclosedUndisclosedMorgan StanleyArticle
2016-06-08$65.0MUndisclosedArticle
2018-01-24$201.2MUndisclosedMultipleArticle
2018-01-25$287.5MUndisclosedMultipleArticle
2019-02-28$350.0MUndisclosedMultipleArticle